Observational Study on the Effects of Placental Heat Shock Protein Peptide on Serum Pain Factors and Joint Range of Motion in Patients with Meniscus Injury

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500105864

Enrollment

Unknown

Registered

2025-07-14

Start date

2025-07-15

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meniscus Tear of the Knee

Interventions

Placental HSP 70 treatment group:none

Conventional treatment group:none

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age between 18 and 65 years, MRI confirmed as knee meniscus injury (grades I-III); 2. Disease course <= 6 months; 3. Voluntarily signed informed consent; 4. No severe liver or kidney dysfunction, autoimmune diseases, or infectious diseases.

Exclusion criteria

Exclusion criteria: 1. Within the past 3 months, underwent knee joint surgery or other biological treatment; 2. Allergic to peptide drugs; 3. Pregnant or lactating women; 4 Comorbid with severe knee osteoarthritis (Kellgren-Lawrence grade >=3).

Design outcomes

Primary

Measure	Time frame
Serum pain factor levels;Active range of motion of knee joint flexion and extension;	—

Secondary

Measure	Time frame
Clinical function scores;Safety indicators;	—

Countries

China

Contacts

Public ContactJiang Hongliang

Xianghe Hospital in Xiong County

xiangheyiyuan120@163.com+86 135 8207 5300

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026